Look for any podcast host, guest or anyone
Showing episodes and shows of

Leslie Citrome MD

Shows

NEI PodcastNEI PodcastE237 - (CME) TD Realities: Patient Quality of Life with Tardive DyskinesiaIn this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Understand the physical, ps...2024-10-2356 minPodcasts360Podcasts360Providing Care for a Person With Agitation in Alzheimer Disease: Resources and EducationIn this podcast, Leslie Citrome, MD, MPH, talks about resources and strategies of care that caregivers of people with agitation in Alzheimer disease can implement. He talks about how caregivers can be supported by clinicians and what tools can be provided to them to ensure that they are providing the best care to the individual experiencing agitation in Alzheimer disease.2024-08-0813 minPsychiatry and Mental HealthPsychiatry and Mental HealthStratified Care: The Role of Switching or Augmentation Therapies Used When Treating Schizophrenia Host: Leslie Citrome, MD, MPH Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or...2024-06-2800 minPsychiatry and Mental HealthPsychiatry and Mental HealthD2 Antagonists Limitations and Challenges: A New Era in Schizophrenia Pathophysiology Host: Leslie Citrome, MD, MPH Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or...2024-06-2800 minPsychiatry and Mental HealthPsychiatry and Mental HealthCase Study: What Do Augmentation and Switching Strategies Look Like in Real-World Clinical Practice? Host: Leslie Citrome, MD, MPH Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or...2024-06-2800 minPsychiatry and Mental HealthPsychiatry and Mental HealthCase Study: What Do Augmentation and Switching Strategies Look Like in Real-World Clinical Practice? Host: Leslie Citrome, MD, MPH Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or...2024-06-2800 minPsychiatry and Mental HealthPsychiatry and Mental HealthD2 Antagonists Limitations and Challenges: A New Era in Schizophrenia Pathophysiology Host: Leslie Citrome, MD, MPH Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or...2024-06-2800 minPsychiatry and Mental HealthPsychiatry and Mental HealthStratified Care: The Role of Switching or Augmentation Therapies Used When Treating Schizophrenia Host: Leslie Citrome, MD, MPH Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or...2024-06-2800 minNEI PodcastNEI PodcastE225 - The PsychopharmaStahlogy Show: Untreatable Dimensions of Psychopathology: Agitation with Dr. Leslie CitromeHow do symptoms of agitation manifest differently in disorders such as bipolar disorder, schizophrenia, and dementia, and what challenges does this pose for assessment? What are the most effective pharmacological treatments for acute agitation in psychiatric patients, and how do you determine the best course of action? How do cultural factors influence the approach to managing agitation in various mental health conditions? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. ...2024-05-1552 minThe Journal of Clinical Psychopharmacology PodcastThe Journal of Clinical Psychopharmacology PodcastCelebrating 70 Years of the First Publication on Antipsychotic Treatment in North America by Heinz E. Lehmann and Gorman E. Hanrahan: Would Their Methodology Still Be Conceivable?In 1954, Dr Heinz Lehmann published the first clinical article on the use of chlorpromazine. Chlorpromazine was the first synthetic drug used to control states of mania and psychomotor excitement, marking the birth of modern psychopharmacology. Seventy years later, the Journal of Clinical Psychopharmacology is highlighting the anniversary of Dr Lehmann’s publication. The January-February 2024 issue of the journal includes a guest editorial that offers a brief history lesson on Dr Lehmann’s contributions. The authors of the editorial are Drs. Pablo Dutra, Richard Balon, and Antonio E. Nardi. In this podcast, the authors of t...2023-12-1532 minNEI PodcastNEI PodcastE205 - 2023 NEI Congress Extended Q&A: Agitation in Dementia with Dr. Leslie CitromeIn this episode, Dr. Leslie Citrome addresses your unanswered questions from his presentation, There’s No Place Like Home: Addressing Agitation in Dementia.2023-11-1707 minCCO Neuroscience PodcastCCO Neuroscience PodcastLong-term Solutions for Long-term Diseases: Using Long-Acting Injectable Antipsychotics in PracticeIn this podcast episode, Leslie Citrome, MD, MPH, and Adam Lowy, MD, share a wealth of knowledge about long-acting injectable (LAI) antipsychotics. Their conversation begins with an overview of the pharmacokinetic profiles of LAI antipsychotics and how they differ from their oral counterparts, as well as injection intervals available with current formulations. The experts also discuss the clinical utility of LAI antipsychotics in psychiatry practice, highlighting their role in assuring medication adherence and their application in both first- and later-episode psychosis. Finally, Drs Citrome and Lowy hit on practical aspects of incorporating LAI antipsychotics into patient care: communicating with...2023-01-1829 minCCO Neuroscience PodcastCCO Neuroscience PodcastAnswering Your Questions About Tardive DyskinesiaGet answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.Presenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry...2022-12-0622 minNEI PodcastNEI PodcastE154 - (CME) The Efficacy and Safety of VMAT2 Inhibitors for the Treatment of Tardive DyskinesiaIn today’s CME episode, Dr. Andrew Cutler will be interviewing Dr. Leslie Citrome about the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e154-cme   Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp Stay updated with email alerts and join our conve...2022-07-271h 04CCO Neuroscience PodcastCCO Neuroscience PodcastDiagnostic Dilemmas in Differentiating Unipolar and Bipolar DepressionIn this episode, Leslie Citrome, MD, MPH, and Manpreet K. Singh, MD, MS, discuss diagnosing unipolar vs bipolar depression. They review why it can be difficult to differentiate between unipolar and bipolar depression; which screening tools they employ, including the rapid mood screener (RMS); how to reduce chances of missing mania; and special tips for differentiating between major depressive disorder (MDD) and bipolar depression in children.  Presenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkManpreet K. Singh, M...2021-08-2031 minNEI PodcastNEI PodcastE114 - TAAR1 Agonists as a Novel Class of Treatment for Psychosis in SchizophreniaIn this episode, Dr. Andrew Cutler interviews Dr. Leslie Citrome on some of the challenges that clinicians face when using traditional methods for the treatment of schizophrenia. They discuss the most current research on the development of TAAR1 agonists as a novel class of psychotropic medication for the treatment of schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD21-TAAR1  Learning Objectives: After completing this educational activity, you should be better able to: Describe the challenges with traditional m...2021-07-2945 minCCO Neuroscience PodcastCCO Neuroscience PodcastDiagnosing TD in Clinical PracticeIn this episode, Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss clinical assessment and diagnosis of tardive dyskinesia (TD). They review using the AIMS exam for identification of dyskinesia in patients in both the clinical setting and via telepsychiatry. They also review how often to perform the AIMS exam, how to assess the results, and why it is important.Presenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkJoseph P. McEvoy, MDProfessorPsychiatry and...2021-06-1228 minNEI PodcastNEI PodcastE108 - Extended Q&A NEI Synapse Half-Day on Novel Strategies to Treat Schizophrenia with Dr. Leslie CitromeWhat are the most frequent comorbidities of schizophrenia? Is there any scientific reason to use any antipsychotic in twice-a-day dosing? In this episode, Dr. Leslie Citrome addresses these questions and more of your unanswered questions from the NEI Synapse Half-Day on Novel Strategies to Treat Schizophrenia in this special NEI Podcast Bonus episode! Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley. Dr...2021-05-2616 minNEI PodcastNEI PodcastE78 - (CME) Help on the Horizon: Novel Treatments in SchizophreniaSchizophrenia is a chronic and debilitating disorder that creates a substantial burden not only for patients but also for their families. The high rates of treatment resistance, relapse rates, and incidence of adverse side effects in patients with schizophrenia suggest that a major treatment gap continues to exist. Given the high rates of treatment resistance, novel strategies and therapeutic approaches beyond D2 receptor blockade are being intensively studied. What are some of these novel approaches? How effective are they in the treatment of schizophrenia? What medications are available, or emerging that target neurotransmitters systems beyond dopamine? In this podcast...2020-07-2337 minNEI PodcastNEI PodcastE51 - Extended Q&A with Dr. Leslie Citrome at NEI Congress!Join us for a fascinating extended Q&A with Dr. Leslie Citrome, where he answers your most pressing questions from his presentation on the assessment and treatment of eating disorders!2019-11-1009 minNEI PodcastNEI PodcastSynapse 2019 Debate with Dr. Roger McIntyre and Dr. Leslie Citrome on the Pros and Cons of Giving an Alzheimer’s Disease DiagnosisShould you tell a patient if they are diagnosed with Alzheimer’s disease? In this exciting debate listen as Dr. McIntyre and Dr. Citrome weigh in on the pros and cons!2019-09-1810 minPsychcastPsychcastTardive dyskenesia masterclassEpisode 52: Tardive dyskinesia masterclass II Leslie Citrome, MD, MPH, returns to the MDedge Psychcast to lecture on Tardive Dyskinesia. In episode 52, where we caught up with Dr. Citrome at the Psychopharmacology Update meeting in Cincinnati, he discusses how to evaluate treatments for TD within the context of P values and effect sizes. Dr. Citrome joined Psychcast host Lorenzo Norris, MD, in the 13th edition of the Psychcast to talk about management of TD. In episode 13, Dr. Citrome said that you can start screening your patients in the waiting room as well as when they w...2019-03-2714 minWCG Talks TrialsWCG Talks TrialsThe Most Pressing Challenges in Psychiatry Clinical Trials with Leslie Citrome, MD, MPHLeslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase. Dr. Citrome has a private practice and is clinical professor of psychiatry and behavioral sciences at New York Medical College in Valhalla.2019-03-0614 minNEI PodcastNEI PodcastEating Disorder Awareness Month with Dr. Leslie Citrome: Binge Eating DisorderFebruary is Eating Disorder Awareness Month! Binge Eating Disorder (BED) is the most common eating disorder, and yet it is one of the most underdiagnosed. In this episode, we interview Dr. Leslie Citrome, an expert in BED about the challenges that prevent accurate diagnosis, and what to do to overcome these. Learn how to communicate effectively with your patients so that this disorder does not go overlooked. Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. His...2019-02-0613 minPsychcastPsychcastDr. Leslie Citrome: addressing tardive dyskinesiaIn this edition of the MDedge Psychast, Lorenzo Norris, MD, welcomes Leslie Citrome, MD, of New York Medical College in Valhalla, NY. for a conversation on the challenges of TD. Sanjay Gupta, MD, of the University of Buffalo, spoke in an MDedge video earlier this year on the importance of using the Abnormal Involuntary Movement Scale to screen for TD and treating the disorder with vesicular monoamine transporter-2 inhibitors. In the episode, Dr. Citrome notes that despite recent advances in pharmacological options, clinicians can be challenged by TD.2018-07-1818 min